RT Journal Article
SR Electronic
T1 Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P1502
VO 44
IS Suppl 58
A1 Hiroyuki Ohbayashi
A1 Yasuhiro Setoguchi
A1 Yoshinosuke Fukuchi
A1 Kai Shibata
A1 Yukinori Sakata
A1 Toshihisa Arai
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P1502.abstract
AB Background/AimMucolytic agents are often used in patients with COPD and bronchial asthma (BA) in Japan to decrease excessive mucus production, which is followed by improvement in dyspnea and QOL. However, the precise mechanism is unknown.Therefore, the actual mechanism of lysozyme hydrochloride (LYS), an oral anti-inflammatory enzyme preparation, in patients with COPD/BA was investigated.MethodThis study was a placebo-controlled, double-blind, randomized, cross-over design. Twenty-fourpatients with COPD and twenty-four patients with BA were enrolled.LYS or placebo was administered for 28 days in each treatment period, with a 28-day washout between the first and second treatment periods.The results ofimpulse oscillometry system (IOS) and spirometry examinations, as well as the changes in the symptoms ofsputum production, were evaluated after the treatment period.ResultsOn IOS examination, resistance of the respiratory system at 5 Hz (R5) levels was significantly improved only in patients with COPD (LYS vs placebo: -0.455 cm H2O/L/s vs 0.095 cmH2O/L/s, p =0.012). Similar trends were also found in R20, X5, and AX. On spirometry, airway function (FEV1)improved in patients with COPD after administration of LYS (LYS vs placebo: 0.062 L vs 0.025 L, p = 0.062). Similar trends were also found in %FEV1 in COPD patients. Subjective symptoms of sputum production also tended to improve only during the LYS treatment period. No adversereactions were observed during the study.ConclusionLYS, a mucolytic agent, may improve the function of peripheral airways, which is followed by improvement in the patients' symptoms and QOL.